{"id":7696,"date":"2026-11-20T14:39:27","date_gmt":"2026-11-20T14:39:27","guid":{"rendered":"https:\/\/borderlessaccess.com\/blog\/?p=7696"},"modified":"2026-11-20T14:39:31","modified_gmt":"2026-11-20T14:39:31","slug":"oncology-panel-cancer-care-decisions","status":"publish","type":"post","link":"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/","title":{"rendered":"From Diagnosis to Prescription: What Three Oncology Studies Reveal About Physician Decisions in Cancer Care"},"content":{"rendered":"<span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Reading Time: <\/span> <span class=\"rt-time\"> 6<\/span> <span class=\"rt-label rt-postfix\">minutes<\/span><\/span>\n<p>Every year, new diagnostics and new treatments are introduced to the field of&nbsp;oncology. But knowing a treatment is not the same as prescribing it.&nbsp;Onclologists always need to choose a new treatment&nbsp;based on the patient\u2019s profile, the strength of the evidence, and what the clinical situation demands. &nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>To examine how those decisions get made, Borderless Access conducted three research studies across different oncology areas: diffuse large B-cell lymphoma (DLBCL), head and neck cancer, and renal cell carcinoma (RCC).&nbsp;<\/p>\n\n\n\n<p>The findings offer a closer look at physician diagnostic practices, perceptions of an upcoming treatment, and the factors influencing brand awareness, usage, and prescribing behaviour.&nbsp;<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_72 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#1_DLBCL_Diagnosis_Understanding_the_Diagnostic_Practices_of_Specialists\" title=\"1. DLBCL Diagnosis: Understanding the Diagnostic Practices of Specialists&nbsp;\">1. DLBCL Diagnosis: Understanding the Diagnostic Practices of Specialists&nbsp;<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#What_diagnostic_methods_do_physicians_commonly_use\" title=\"What diagnostic methods do physicians commonly use?&nbsp;\">What diagnostic methods do physicians commonly use?&nbsp;<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#How_familiar_are_physicians_with_COO_classification\" title=\"How familiar are physicians with COO classification?&nbsp;\">How familiar are physicians with COO classification?&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#What_does_this_reveal\" title=\"What does this reveal?&nbsp;\">What does this reveal?&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#2_Head_and_Neck_Cancer_Care_What_Influences_Physicians_Willingness_to_Prescribe_an_Upcoming_Treatment\" title=\"2. Head and Neck Cancer Care: What Influences Physicians&#8217; Willingness to Prescribe an Upcoming Treatment?&nbsp;\">2. Head and Neck Cancer Care: What Influences Physicians&#8217; Willingness to Prescribe an Upcoming Treatment?&nbsp;<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#How_likely_are_physicians_to_prescribe_the_upcoming_treatment\" title=\"How likely are physicians to prescribe the upcoming treatment?&nbsp;\">How likely are physicians to prescribe the upcoming treatment?&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#What_could_influence_treatment_adoption\" title=\"What could influence treatment adoption?&nbsp;\">What could influence treatment adoption?&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#Which_treatment-related_barriers_deserve_attention\" title=\"Which treatment-related barriers deserve attention?&nbsp;\">Which treatment-related barriers deserve attention?&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#What_does_this_reveal-2\" title=\"What does this reveal?&nbsp;\">What does this reveal?&nbsp;<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#3_Renal_Cell_Carcinoma_What_Drives_Brand_Prescription_Among_Oncologists\" title=\"3. Renal Cell Carcinoma: What Drives Brand Prescription Among Oncologists?&nbsp;\">3. Renal Cell Carcinoma: What Drives Brand Prescription Among Oncologists?&nbsp;<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#Prescription_Drivers_Understanding_What_Influences_Oncologist_Choices\" title=\"Prescription Drivers: Understanding What Influences Oncologist Choices&nbsp;\">Prescription Drivers: Understanding What Influences Oncologist Choices&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#Brand_Awareness_and_Usage_Two_Different_Measures\" title=\"Brand Awareness and Usage: Two Different Measures&nbsp;\">Brand Awareness and Usage: Two Different Measures&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#Brand_Commitment_and_Actual_Prescription_Behaviour\" title=\"Brand Commitment and Actual Prescription Behaviour&nbsp;\">Brand Commitment and Actual Prescription Behaviour&nbsp;<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#4_What_Do_These_Three_Oncology_Studies_Reveal_About_Physician_Decision-Making\" title=\"4. What Do These Three Oncology Studies Reveal About Physician Decision-Making?&nbsp;\">4. What Do These Three Oncology Studies Reveal About Physician Decision-Making?&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#Turning_Physician_Insights_into_More_Informed_Healthcare_Strategies\" title=\"Turning Physician Insights into More Informed Healthcare Strategies&nbsp;\">Turning Physician Insights into More Informed Healthcare Strategies&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\" id=\"h-1-dlbcl-diagnosis-understanding-the-diagnostic-practices-of-specialists-nbsp\" style=\"font-size:26px\"><span class=\"ez-toc-section\" id=\"1_DLBCL_Diagnosis_Understanding_the_Diagnostic_Practices_of_Specialists\"><\/span><strong>1. DLBCL Diagnosis: Understanding the Diagnostic Practices of Specialists<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-2-1-1024x536.webp\" alt=\"\" class=\"wp-image-7712\" srcset=\"https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-2-1-1024x536.webp 1024w, https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-2-1-300x157.webp 300w, https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-2-1-768x402.webp 768w, https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-2-1-1536x804.webp 1536w, https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-2-1-2048x1072.webp 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Accurate diagnosis plays an important role in determining the course of cancer care. Understanding the diagnostic methods physicians rely on can provide pharmaceutical companies with a clearer picture of existing clinical practices and potential gaps in the diagnostic landscape.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><a href=\"https:\/\/borderlessaccess.com\/case-studies\/hematology-panel-dlbcl-diagnosis-insights\">A Borderless Access study <\/a>involving 100 hematologists and hemato-oncologists across the EU5 markets and the USA examined how specialists approach the diagnosis of diffuse large B-cell lymphoma (DLBCL).&nbsp;<\/p>\n\n\n\n<p>Conducted through a 10-minute online survey, the research explored the diagnostic methods physicians commonly use, including imaging, tissue or lymph node biopsies, and cell-of-origin (COO) classification.&nbsp;<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-diagnostic-methods-do-physicians-commonly-use-nbsp\" style=\"font-size:22px\"><span class=\"ez-toc-section\" id=\"What_diagnostic_methods_do_physicians_commonly_use\"><\/span><strong>What diagnostic methods do physicians commonly use?<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The study examined the diagnostic methods specialists rely on when managing DLBCL patients.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Imaging tests and tissue or lymph node biopsies emerged as the commonly reported diagnostic methods. The research also examined the use of complete blood counts, bone marrow biopsies, and lumbar punctures.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>These findings provide a view of the different diagnostic approaches reported by specialists and the role of various methods in current DLBCL diagnostic practices.&nbsp;<\/p>\n\n\n\n<div style=\"height:26px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-familiar-are-physicians-with-coo-classification-nbsp\" style=\"font-size:22px\"><span class=\"ez-toc-section\" id=\"How_familiar_are_physicians_with_COO_classification\"><\/span><strong>How familiar are physicians with COO classification?<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Cell-of-origin classification is an important aspect of understanding DLBCL. The research examined physicians&#8217; familiarity with this approach, including the use of immunohistochemistry (IHC) and gene expression testing.&nbsp;<\/p>\n\n\n\n<p>Among the surveyed physicians, 45% reported that COO classification was done through IHC, while 35% identified gene expression as the method used. Another 20% were unsure how COO classification was determined.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>The study also examined when these tests were conducted across different stages of the patient&#8217;s treatment journey, including initial diagnosis, during first-line treatment before switching to second-line treatment, and during second-line treatment before switching to third-line or later treatment.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-does-this-reveal-nbsp\" style=\"font-size:22px\"><span class=\"ez-toc-section\" id=\"What_does_this_reveal\"><\/span><strong>What does this reveal?<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The findings highlight the importance of understanding not only which diagnostic methods physicians use but also their familiarity with different classification approaches and when these are incorporated into clinical practice.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>For pharmaceutical companies, these insights provide a clearer understanding of the existing diagnostic landscape and can help inform broader business strategy and operations.&nbsp;<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-2-head-and-neck-cancer-care-what-influences-physicians-willingness-to-prescribe-an-upcoming-treatment-nbsp\" style=\"font-size:26px\"><span class=\"ez-toc-section\" id=\"2_Head_and_Neck_Cancer_Care_What_Influences_Physicians_Willingness_to_Prescribe_an_Upcoming_Treatment\"><\/span><strong>2. Head and Neck Cancer Care: What Influences Physicians&#8217; Willingness to Prescribe an Upcoming Treatment?<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-3-Opt-2-1024x536.webp\" alt=\"\" class=\"wp-image-7711\" srcset=\"https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-3-Opt-2-1024x536.webp 1024w, https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-3-Opt-2-300x157.webp 300w, https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-3-Opt-2-768x402.webp 768w, https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-3-Opt-2-1536x804.webp 1536w, https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-3-Opt-2-2048x1072.webp 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Developing an oncology treatment involves understanding not only its potential clinical value but also how physicians perceive it and what could influence its eventual adoption.&nbsp;Physicians may respond positively to a treatment&#8217;s perceived efficacy and safety, but their willingness to prescribe it can also depend on practical considerations and potential barriers to adoption.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>To understand these factors, <a href=\"https:\/\/borderlessaccess.com\/case-studies\/oncology-panel-head-neck-cancer\">Borderless Access conducted research<\/a> among 50 radiation oncologists across the USA, Germany, France, and Italy.&nbsp;The 30-minute online survey examined physician perceptions of an upcoming head and neck cancer treatment, including its perceived efficacy and safety, prescribing likelihood, adoption challenges, and potential barriers to its use.&nbsp;<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-how-likely-are-physicians-to-prescribe-the-upcoming-treatment-nbsp\" style=\"font-size:22px\"><span class=\"ez-toc-section\" id=\"How_likely_are_physicians_to_prescribe_the_upcoming_treatment\"><\/span><strong>How likely are physicians to prescribe the upcoming treatment?<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The study findings indicated positive stated prescribing intent among the surveyed radiation oncologists.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<ul class=\"wp-block-list\">\n<li style=\"font-size:18px\"><strong>50%<\/strong> said they would definitely prescribe the treatment once available.&nbsp;<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li style=\"font-size:18px\"><strong>30%<\/strong> said they would probably prescribe it once available.&nbsp;<\/li>\n<\/ul>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Together, these responses indicate that 80% of the surveyed physicians expressed positive stated prescribing intent.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>However, interest in a treatment that is still under development does not necessarily translate into future prescribing behaviour. Understanding the considerations that influence physicians&#8217; willingness to prescribe it is equally important.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-could-influence-treatment-adoption-nbsp\" style=\"font-size:22px\"><span class=\"ez-toc-section\" id=\"What_could_influence_treatment_adoption\"><\/span><strong>What could influence treatment adoption?<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The study examined several practical and operational challenges associated with the potential adoption of the upcoming treatment.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>These included:&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<ul class=\"wp-block-list\">\n<li style=\"font-size:18px\">Whether physicians&#8217; practices were adequately equipped.&nbsp;<\/li>\n<\/ul>\n\n\n\n<ul style=\"font-size:18px\" class=\"wp-block-list\">\n<li>Time constraints associated with treatment administration.&nbsp;<\/li>\n<\/ul>\n\n\n\n<ul style=\"font-size:18px\" class=\"wp-block-list\">\n<li>Logistical challenges.&nbsp;<\/li>\n<\/ul>\n\n\n\n<ul style=\"font-size:18px\" class=\"wp-block-list\">\n<li>Availability of staff.&nbsp;<\/li>\n<\/ul>\n\n\n\n<ul style=\"font-size:18px\" class=\"wp-block-list\">\n<li>Infrastructure limitations.&nbsp;<\/li>\n<\/ul>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>These considerations highlight why evaluating physician interest alone may not provide a complete picture of potential treatment adoption.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-which-treatment-related-barriers-deserve-attention-nbsp\" style=\"font-size:22px\"><span class=\"ez-toc-section\" id=\"Which_treatment-related_barriers_deserve_attention\"><\/span><strong>Which treatment-related barriers deserve attention?<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The research also explored specific barriers that could influence physicians&#8217; willingness to prescribe the treatment.&nbsp;<\/p>\n\n\n\n<p>These included concerns around treatment efficacy, limitations related to the indicated patient population, and practical considerations associated with administration.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>The study specifically examined factors such as:&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<ul style=\"font-size:18px\" class=\"wp-block-list\">\n<li>Duration of intravenous infusion.&nbsp;<\/li>\n<\/ul>\n\n\n\n<ul style=\"font-size:18px\" class=\"wp-block-list\">\n<li>Time constraints between intravenous infusion and the start of intramuscular injection.&nbsp;<\/li>\n<\/ul>\n\n\n\n<ul style=\"font-size:18px\" class=\"wp-block-list\">\n<li>The need for product administration before each intramuscular injection.&nbsp;<\/li>\n<\/ul>\n\n\n\n<ul style=\"font-size:18px\" class=\"wp-block-list\">\n<li>Concerns about treatment efficacy.&nbsp;<\/li>\n<\/ul>\n\n\n\n<ul style=\"font-size:18px\" class=\"wp-block-list\">\n<li>Limitations related to the patient population indicated for treatment.&nbsp;<\/li>\n<\/ul>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Together, these findings bring attention to the clinical and practical considerations that may influence a physician&#8217;s willingness to prescribe an upcoming treatment.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-does-this-reveal-nbsp-0\" style=\"font-size:22px\"><span class=\"ez-toc-section\" id=\"What_does_this_reveal-2\"><\/span><strong>What does this reveal?<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Understanding both positive perceptions and potential adoption barriers provides a more balanced view of a treatment&#8217;s market potential.&nbsp;The findings helped the client assess opportunities for the treatment under development, identify gaps, and support strategic planning and resource allocation around patient care and treatment outcomes.&nbsp;<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-3-renal-cell-carcinoma-what-drives-brand-prescription-among-oncologists-nbsp\" style=\"font-size:26px\"><span class=\"ez-toc-section\" id=\"3_Renal_Cell_Carcinoma_What_Drives_Brand_Prescription_Among_Oncologists\"><\/span><strong>3. Renal Cell Carcinoma: What Drives Brand Prescription Among Oncologists?<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"537\" src=\"https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-1-Opt-1-1-1024x537.webp\" alt=\"\" class=\"wp-image-7709\" srcset=\"https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-1-Opt-1-1-1024x537.webp 1024w, https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-1-Opt-1-1-300x157.webp 300w, https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-1-Opt-1-1-768x403.webp 768w, https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-1-Opt-1-1-1536x805.webp 1536w, https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Blog-1-Opt-1-1-2048x1073.webp 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>While understanding perceptions of an upcoming treatment is important before launch, pharmaceutical companies also need to understand how existing brands are viewed and used in clinical practice.&nbsp;In renal cell carcinoma (RCC), awareness of a treatment does not necessarily indicate its position in physicians&#8217; prescribing decisions. Understanding what drives brand selection requires examining awareness, usage, perceptions, and treatment requirements together.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><a href=\"https:\/\/borderlessaccess.com\/case-studies\/cancer-panel-rcc-treatment-insights\">Borderless Access conducted a study<\/a> involving 500 medical oncologists and hematologists across the USA through a 60-minute online survey.&nbsp;<\/p>\n\n\n\n<p>The research examined physician perceptions of existing RCC treatment brands, the factors influencing prescription decisions, and treatment needs across neoadjuvant and metastatic settings.&nbsp;<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-prescription-drivers-understanding-what-influences-oncologist-choices-nbsp\" style=\"font-size:22px\"><span class=\"ez-toc-section\" id=\"Prescription_Drivers_Understanding_What_Influences_Oncologist_Choices\"><\/span><strong>Prescription Drivers: Understanding What Influences Oncologist Choices<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The study compiled the factors influencing brand prescription, providing a clearer understanding of the attributes and considerations shaping oncologist choices.&nbsp;Rather than focusing only on which brands physicians recognise, the research examined the factors contributing to their treatment selections.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Understanding these drivers helps pharmaceutical companies move beyond brand familiarity to examine what influences treatment choices.&nbsp;<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-brand-awareness-and-usage-two-different-measures-nbsp\" style=\"font-size:22px\"><span class=\"ez-toc-section\" id=\"Brand_Awareness_and_Usage_Two_Different_Measures\"><\/span><strong>Brand Awareness and Usage: Two Different Measures<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The research assessed brand awareness alongside reported brand usage to understand the relationship between familiarity and prescribing behaviour.&nbsp;Separating these measures helps distinguish between physicians knowing a treatment and reporting its use in clinical practice.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>This distinction is important when evaluating brand performance, as awareness alone cannot establish a treatment&#8217;s place in prescribing behaviour.&nbsp;The study also examined brand awareness and willingness to prescribe across first-line and second-line RCC treatment.&nbsp;It also considered current and future therapy needs in neoadjuvant and metastatic settings.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Taking these factors&nbsp;into consideration&nbsp;provided a broader view of the treatment contexts in which oncologists evaluate available brands and consider different treatment options.&nbsp;<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-brand-commitment-and-actual-prescription-behaviour-nbsp\" style=\"font-size:22px\"><span class=\"ez-toc-section\" id=\"Brand_Commitment_and_Actual_Prescription_Behaviour\"><\/span><strong>Brand Commitment and Actual Prescription Behaviour<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Another important dimension of the research was the relationship between brand commitment and prescription behaviour.&nbsp;The study generated real-time prescription insights to examine this relationship, offering a more nuanced understanding of brand performance.&nbsp;For pharmaceutical companies, this distinction can help identify where brand perceptions and reported prescribing behaviour may differ.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Translating Prescription Insights into Brand Communication&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>The findings enabled the client&#8217;s marketing teams to customise brand messaging for oncologists around the key drivers of prescription.&nbsp;By connecting awareness, usage, perceptions, and prescribing behaviour, the research provided a stronger basis for brand communication and helped the client better understand opportunities across different treatment settings.&nbsp;<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-4-what-do-these-three-oncology-studies-reveal-about-physician-decision-making-nbsp\" style=\"font-size:26px\"><span class=\"ez-toc-section\" id=\"4_What_Do_These_Three_Oncology_Studies_Reveal_About_Physician_Decision-Making\"><\/span><strong>4. What Do These Three Oncology Studies Reveal About Physician Decision-Making?<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Although the three studies focused on different oncology conditions and research objectives, they highlight a common consideration: understanding physician decisions requires looking beyond individual measures.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Each study offers a different perspective on the factors shaping oncology care.&nbsp;<\/p>\n\n\n\n<div style=\"height:13px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Research area<\/strong>&nbsp;<\/td><td><strong>What the research uncovered<\/strong>&nbsp;<\/td><\/tr><tr><td>DLBCL diagnostic practices&nbsp;<\/td><td>Diagnostic methods, biopsy practices, COO classification familiarity, and timing&nbsp;<\/td><\/tr><tr><td>Emerging head and neck cancer treatment&nbsp;<\/td><td>Physician perceptions, stated prescribing intent, and potential adoption barriers&nbsp;<\/td><\/tr><tr><td>RCC brand research&nbsp;<\/td><td>Prescription drivers, brand awareness, usage, treatment-line considerations, and brand commitment&nbsp;<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Together, these findings demonstrate three important dimensions of healthcare research.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong>Clinical practices provide context<\/strong><\/p>\n\n\n\n<p> Examining diagnostic methods and classification practices helps establish how specialists approach a particular indication.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong>Treatment perceptions reveal potential interest<\/strong><\/p>\n\n\n\n<p>Understanding how physicians evaluate an upcoming treatment, alongside their stated prescribing intent, provides an indication of its potential market reception.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong>Prescription drivers offer a deeper view of brand behaviour<\/strong><\/p>\n\n\n\n<p>Examining awareness alongside usage and the factors influencing prescription helps pharmaceutical companies understand how existing brands are positioned in clinical practice.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Each factor answers a different business question. When examined together, they provide a broader understanding of the clinical and behavioural considerations shaping physician decisions.&nbsp;<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-turning-physician-insights-into-more-informed-healthcare-strategies-nbsp\" style=\"font-size:26px\"><span class=\"ez-toc-section\" id=\"Turning_Physician_Insights_into_More_Informed_Healthcare_Strategies\"><\/span><strong>Turning Physician Insights into More Informed Healthcare Strategies<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The three studies highlight how oncology treatment decisions are shaped by multiple considerations, from diagnostic practices and treatment perceptions to adoption barriers and brand-related prescribing factors.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>For pharmaceutical companies, understanding these decisions requires looking beyond individual measures such as brand awareness or prescribing intent. It means examining how physicians evaluate treatment options, what influences their choices, and which clinical or practical considerations may affect their decisions across different indications and stages of care.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Through its healthcare research, Borderless Access has examined different dimensions of oncology decision-making, including diagnostic practices in DLBCL, perceptions of an upcoming head and neck cancer treatment, and brand awareness and prescription drivers in RCC.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>These studies demonstrate how focused physician research can help pharmaceutical teams develop a clearer understanding of clinical practices, identify potential opportunities and barriers, and connect physician perspectives with broader business and marketing objectives.&nbsp;<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Ultimately, better-informed healthcare strategies begin with understanding the specialists, considerations, and clinical contexts that shape treatment decisions.&nbsp;<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p><span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Reading Time: <\/span> <span class=\"rt-time\"> 6<\/span> <span class=\"rt-label rt-postfix\">minutes<\/span><\/span>Every year, new diagnostics and new treatments are introduced to the field of&nbsp;oncology. But knowing a treatment is not the same as prescribing it.&nbsp;Onclologists always need to choose a new treatment&nbsp;based on the patient\u2019s profile, the strength of the evidence, and what the clinical situation demands. &nbsp; To examine how those decisions get made, Borderless Access conducted three research studies across different oncology areas: diffuse large B-cell lymphoma (DLBCL), head and neck cancer, and renal cell carcinoma (RCC).&nbsp; The findings offer a closer look at physician diagnostic practices, perceptions of an upcoming treatment, and the factors influencing brand awareness, usage,&#8230;<\/p>\n","protected":false},"author":21,"featured_media":7707,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[83],"tags":[],"class_list":["post-7696","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare-medical"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.1 (Yoast SEO v22.1) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Oncology Panel: Insights into Cancer Care Decisions<\/title>\n<meta name=\"description\" content=\"Explore how a cancer panel of oncologists and hematologists influences diagnosis, treatment adoption, and prescribing decisions in oncology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"From Diagnosis to Prescription: What Three Oncology Studies Reveal About Physician Decisions in Cancer Care\" \/>\n<meta property=\"og:description\" content=\"Explore how a cancer panel of oncologists and hematologists influences diagnosis, treatment adoption, and prescribing decisions in oncology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Research Insights -Borderless Access Blog\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-20T14:39:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-20T14:39:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Cover-Opt-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1250\" \/>\n\t<meta property=\"og:image:height\" content=\"715\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Prajwal S\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Prajwal S\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/\",\"url\":\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/\",\"name\":\"Oncology Panel: Insights into Cancer Care Decisions\",\"isPartOf\":{\"@id\":\"https:\/\/borderlessaccess.com\/blog\/#website\"},\"datePublished\":\"2026-11-20T14:39:27+00:00\",\"dateModified\":\"2026-11-20T14:39:31+00:00\",\"author\":{\"@id\":\"https:\/\/borderlessaccess.com\/blog\/#\/schema\/person\/7cef99a161a6dc7f1d93f063980cd0fd\"},\"description\":\"Explore how a cancer panel of oncologists and hematologists influences diagnosis, treatment adoption, and prescribing decisions in oncology.\",\"breadcrumb\":{\"@id\":\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/borderlessaccess.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"From Diagnosis to Prescription: What Three Oncology Studies Reveal About Physician Decisions in Cancer Care\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/borderlessaccess.com\/blog\/#website\",\"url\":\"https:\/\/borderlessaccess.com\/blog\/\",\"name\":\"Market Research Insights - Borderless Access Blog\",\"description\":\"Gain fresh perspectives and insights on global trends for your business growth. Access the latest consumer research and business data insights here.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/borderlessaccess.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/borderlessaccess.com\/blog\/#\/schema\/person\/7cef99a161a6dc7f1d93f063980cd0fd\",\"name\":\"Prajwal S\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/borderlessaccess.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/09\/Prajwal-Profile-Image-96x96.webp\",\"contentUrl\":\"https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/09\/Prajwal-Profile-Image-96x96.webp\",\"caption\":\"Prajwal S\"},\"description\":\"Prajwal S, Associate Director \u2013 Marketing &amp; Growth at Borderless Access, leads business growth initiatives across B2B and consumer markets. With expertise spanning across data analytics, performance marketing, demand generation, and digital transformation, he helps strengthen brand visibility and customer engagement with measurable business outcomes.\",\"sameAs\":[\"https:\/\/borderlessaccess.com\/\"],\"url\":\"https:\/\/borderlessaccess.com\/blog\/author\/cindy-bowdan\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Oncology Panel: Insights into Cancer Care Decisions","description":"Explore how a cancer panel of oncologists and hematologists influences diagnosis, treatment adoption, and prescribing decisions in oncology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/","og_locale":"en_US","og_type":"article","og_title":"From Diagnosis to Prescription: What Three Oncology Studies Reveal About Physician Decisions in Cancer Care","og_description":"Explore how a cancer panel of oncologists and hematologists influences diagnosis, treatment adoption, and prescribing decisions in oncology.","og_url":"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/","og_site_name":"Market Research Insights -Borderless Access Blog","article_published_time":"2026-11-20T14:39:27+00:00","article_modified_time":"2026-11-20T14:39:31+00:00","og_image":[{"width":1250,"height":715,"url":"https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/11\/Cover-Opt-1.jpg","type":"image\/jpeg"}],"author":"Prajwal S","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Prajwal S","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/","url":"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/","name":"Oncology Panel: Insights into Cancer Care Decisions","isPartOf":{"@id":"https:\/\/borderlessaccess.com\/blog\/#website"},"datePublished":"2026-11-20T14:39:27+00:00","dateModified":"2026-11-20T14:39:31+00:00","author":{"@id":"https:\/\/borderlessaccess.com\/blog\/#\/schema\/person\/7cef99a161a6dc7f1d93f063980cd0fd"},"description":"Explore how a cancer panel of oncologists and hematologists influences diagnosis, treatment adoption, and prescribing decisions in oncology.","breadcrumb":{"@id":"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/borderlessaccess.com\/blog\/oncology-panel-cancer-care-decisions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/borderlessaccess.com\/blog\/"},{"@type":"ListItem","position":2,"name":"From Diagnosis to Prescription: What Three Oncology Studies Reveal About Physician Decisions in Cancer Care"}]},{"@type":"WebSite","@id":"https:\/\/borderlessaccess.com\/blog\/#website","url":"https:\/\/borderlessaccess.com\/blog\/","name":"Market Research Insights - Borderless Access Blog","description":"Gain fresh perspectives and insights on global trends for your business growth. Access the latest consumer research and business data insights here.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/borderlessaccess.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/borderlessaccess.com\/blog\/#\/schema\/person\/7cef99a161a6dc7f1d93f063980cd0fd","name":"Prajwal S","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/borderlessaccess.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/09\/Prajwal-Profile-Image-96x96.webp","contentUrl":"https:\/\/borderlessaccess.com\/blog\/wp-content\/uploads\/2026\/09\/Prajwal-Profile-Image-96x96.webp","caption":"Prajwal S"},"description":"Prajwal S, Associate Director \u2013 Marketing &amp; Growth at Borderless Access, leads business growth initiatives across B2B and consumer markets. With expertise spanning across data analytics, performance marketing, demand generation, and digital transformation, he helps strengthen brand visibility and customer engagement with measurable business outcomes.","sameAs":["https:\/\/borderlessaccess.com\/"],"url":"https:\/\/borderlessaccess.com\/blog\/author\/cindy-bowdan\/"}]}},"_links":{"self":[{"href":"https:\/\/borderlessaccess.com\/blog\/wp-json\/wp\/v2\/posts\/7696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/borderlessaccess.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/borderlessaccess.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/borderlessaccess.com\/blog\/wp-json\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/borderlessaccess.com\/blog\/wp-json\/wp\/v2\/comments?post=7696"}],"version-history":[{"count":14,"href":"https:\/\/borderlessaccess.com\/blog\/wp-json\/wp\/v2\/posts\/7696\/revisions"}],"predecessor-version":[{"id":7726,"href":"https:\/\/borderlessaccess.com\/blog\/wp-json\/wp\/v2\/posts\/7696\/revisions\/7726"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/borderlessaccess.com\/blog\/wp-json\/wp\/v2\/media\/7707"}],"wp:attachment":[{"href":"https:\/\/borderlessaccess.com\/blog\/wp-json\/wp\/v2\/media?parent=7696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/borderlessaccess.com\/blog\/wp-json\/wp\/v2\/categories?post=7696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/borderlessaccess.com\/blog\/wp-json\/wp\/v2\/tags?post=7696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}